(Reuters) – Boston Scientific Corp , which is in the midst of an attempted turnaround, reported weak sales of its heart stents and provided a disappointing fourth-quarter company sales forecast, sending its shares almost 7 percent lower on Thursday.
Reuters: Business News article archive.
Comments are closed.
Visiting France? Get the best Paris deals at LinkParis.com before your trip.
Arrange a visit to see the D-Day landing beaches in Normandy, the castles of the Loire Valley, a Mont St. Michel tour, Paris Day Trips and more!
Get your NewsFlares.com now!
Email corrections to:
Send news tips to:
Write for us: